Non-Invasive Assessment of Wound Healing With Optical Methods
1 other identifier
observational
38
1 country
1
Brief Summary
The objective of this project is to further the development of a non-invasive optically based NIR (Near Infrared) device to enable the quantitative diagnosis, monitoring and treatment optimization of chronic wounds (especially diabetic) in a clinical setting. The end goal of this project is a portable and compact device that would be simple to operate by minimally trained health care personnel. Our animal studies have shown that the early healing of chronic wounds can be characterized by absorption and scattering of light at near infrared wavelengths ranging from 680 nm to 950 nm. If our project is successful we will be providing the clinician the ability to predict if a wound is healing and if a particular treatment is successful in accelerating healing before any changes are observed by wound size contraction or other visible clinical signs. Our hope is that the fNIR optical device will provide conclusive therapeutic treatment information as early as 5 weeks after initial evaluation, before it would be obvious on gross examination of the patient.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Sep 2007
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2007
CompletedFirst Submitted
Initial submission to the registry
December 20, 2007
CompletedFirst Posted
Study publicly available on registry
December 21, 2007
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2014
CompletedMarch 30, 2017
March 1, 2017
6.8 years
December 20, 2007
March 28, 2017
Conditions
Outcome Measures
Primary Outcomes (1)
diffuse near infrared spectroscopy measurements
The end goal of this project is a portable and compact device that would be simple to operate by minimally trained health care personnel and is comparable to SOC doppler.
3 years
Study Arms (2)
Patients with a diabetic wound
Patients with a diabetic wound
Control
Patients without a diabetic wound
Interventions
Measure blood flow to diabetic wounds
Eligibility Criteria
Recruited patients will be patients with diabetes who have chronic wounds and will likely have other co-morbidities associated with chronic diabetes. Control subjects do not have diabetes and do not have wounds.
You may qualify if:
- Subjects must be 18-65 years of age
- Subjects must have no history of diabetes
- Subjects must have no history of vascular disease
- Subjects must have no findings of vascular disease on physical examination
- Subjects who are not allergic to Tegaderm
- Subjects must be 18-65 years of age
- Subjects must have documented diabetes mellitus for at least 6 months.
- Subjects must have at least one documented chronic wound for a minimum 8 weeks.
- A chronic wound is defined as any wound that has not healed after 8 weeks and has a minimum surface area of 1cm2. There is no maximum wound size.
- Wound(s) must be secondary to the complications of diabetes, including vascular disease neuropathy, or both.
- Wounds must be on the ankles or feet
- Subjects who are not allergic to Tegaderm
You may not qualify if:
- Subject must not be \<18 or \>65 years of age
- Subjects with major infections, abscesses, or untreated osteomyelitis will be excluded until appropriately treated.
- Subjects will not be excluded based upon the existence of other co-morbidities associated with chronic diabetes, including retinopathy, nephropathy, peripheral neuropathy, or cardiovascular disease except as follows:
- Subjects who have moderate to severe vascular insufficiency (defined as ankle brachial index \<0.75 or toe-brachial index \<0.5)
- Subjects who are unable to return for weekly follow-up appointments will not be included.
- Pregnant or lactating people will not be invited to participate.
- Subjects who are allergic to Tegaderm
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Drexel University College of Medicine Wound Care Center
Philadelphia, Pennsylvania, 19102, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Michael S Weingarten, M.D.
Drexel University College of Medicine
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 20, 2007
First Posted
December 21, 2007
Study Start
September 1, 2007
Primary Completion
June 1, 2014
Study Completion
June 1, 2014
Last Updated
March 30, 2017
Record last verified: 2017-03